Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature | Zendy

Ali Al Sbihi | Zendy; Nouraldeen Manasrah | Zendy; Dahlia Sano | Zendy

Open Access

Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature

Author(s) -

Ali Al Sbihi,

Nouraldeen Manasrah,

Dahlia Sano

Publication year - 2022

Publication title -

european journal of case reports in internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2284-2594

DOI - 10.12890/2022_003216

Subject(s) - lenalidomide , medicine , multiple myeloma , covid-19 , series (stratigraphy) , intensive care medicine , pediatrics , virology , disease , paleontology , outbreak , infectious disease (medical specialty) , biology

We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research